Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Cost of Revenue (2016 - 2025)

Adma Biologics (ADMA) has disclosed Cost of Revenue for 13 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 99.01% year-over-year to $1.1 million, compared with a TTM value of $4.8 million through Dec 2025, down 97.66%, and an annual FY2025 reading of $4.8 million, down 97.66% over the prior year.
  • Cost of Revenue was $1.1 million for Q4 2025 at Adma Biologics, down from $1.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $166.3 million in Q4 2023 and bottomed at -$65.2 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $19.2 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Cost of Revenue crashed 176.0% in 2021, then skyrocketed 7005.43% in 2024.
  • Year by year, Cost of Revenue stood at -$44.6 million in 2021, then tumbled by 46.09% to -$65.2 million in 2022, then soared by 355.23% to $166.3 million in 2023, then plummeted by 31.84% to $113.4 million in 2024, then plummeted by 99.01% to $1.1 million in 2025.
  • Business Quant data shows Cost of Revenue for ADMA at $1.1 million in Q4 2025, $1.3 million in Q3 2025, and $1.2 million in Q2 2025.